Author:
Bezdieniezhnykh N.,Lykhova A.,Kozak T.,Zadvornyi T.,Borikun T.,Voronina O.,Lukianova N.
Abstract
Abstract
Background
The assessment of biosafety of pharmacologically active substances is crucial for determining the feasibility of their medical use. There are controversial issues regarding the use of substances of different origins as implants.
Methods
We have conducted the comprehensive studies to determine the in vivo toxicity and in vitro genotoxicity of new generation of hydrophilic gel for implantation (production name of the substance “Activegel”) to detail its characteristics and assess its biosafety.
Results
In vivo studies have shown the absence of clinical manifestations of intoxication in animals and no abnormalities in their physiological condition, general and biochemical blood tests. Evaluation of the site of the gel application showed no inflammatory reaction and evidenced on normal state of tissues of animal skin. The results of the genotoxicity test indicated that the gel did not affect the parameters of DNA comets and the formation of micronuclei, accordingly, had no genotoxic effect on human peripheral blood lymphocytes. When studying the effect of the gel on malignantly transformed cells in vitro, it was found that the gel for implantation did not change the proliferative activity and viability of human breast cancer cells.
Conclusions
Comprehensive in vitro and in vivo study using various experimental model systems showed that the hydrophilic gel for implantation “Activegel” is non-toxic.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference24 articles.
1. Krewski D, Acosta D Jr, Andersen M, et al. Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health B Crit Rev. 2010;13(2–4):51–138.
2. Parasuraman S. Toxicological screening. J Pharmacol Pharmacother. 2011;2(2):74–9.
3. Thorpe AA, Freeman C, Farthing P, et al. In vivo safety and efficacy testing of a thermally triggered injectable hydrogel scaffold for bone regeneration and augmentation in a rat model. Oncotarget. 2018;9(26):18277–95.
4. Saline, silicone gel, and alternative breast implants guidance for industry and Food and Drug Administration staff document issued on September 29, 2020. Document originally issued on November 17, 2006. https://www.fda.gov/media/71081/download
5. Vieira RAC, Ribeiro LM, GFA C, et al. Effectiveness and Safety of Implant-Based Breast Reconstruction in Locally Advanced Breast Carcinoma: A Matched Case-Control Study. Breast Care. 2019;14:200–10.